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Members of the tumor necrosis factor receptor (TNFR)
superfamily have an important role in the induction of
cellular signals resulting in cell growth, differentiation
and death [1]. TNFR-1 recruits and assembles a
signaling complex containing a number of death
domain (DD)-containing proteins, including the adaptor
protein TRADD and the serine/threonine kinase RIP [2],
which mediates TNF-induced NF-kB activation [3]. RIP
also recruits caspase-2 to the TNFR-1 signaling
complex via the adaptor protein RAIDD, which contains
a DD and a caspase-recruiting domain (CARD) [4]. Here,
we have identified a RIP-like kinase, termed CARDIAK
(for CARD-containing interleukin (IL)-1b converting
enzyme (ICE) associated kinase), which contains a
serine/threonine kinase domain and a carboxy-terminal
CARD [5]. Overexpression of CARDIAK induced the
activation of both NF-kB and Jun N-terminal kinase
(JNK). CARDIAK interacted with the TNFR-associated
factors TRAF-1 and TRAF-2, and a dominant-negative
form of TRAF-2 inhibited CARDIAK-induced NF-kB
activation. Interestingly, CARDIAK specifically
interacted with the CARD of caspase-1 (previously
known as ICE), and this interaction correlated with the
processing of pro-caspase-1 and the formation of the
active p20 subunit of caspase-1. Together, these data
suggest that CARDIAK may be involved in NF-kB/JNK
signaling and in the generation of the proinflammatory
cytokine IL-1b through activation of caspase-1.
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Results and discussion
To identify CARD-containing proteins, we screened
public databases using a generalized profile [6] con-
structed from all currently known CARD sequences [5].
An expressed sequence tag clone (EST clone 799136)
containing a CARD was identified (GenBank accession
AF064824) and corresponded to a protein of 540 amino
acids with an estimated molecular mass of 62 kDa and an
overall structural organization similar to RIP (Figure 1a).
The amino-terminal region (amino acids 18–294) contains
a predicted serine/threonine kinase domain which is most
homologous to the kinase domain of RIP (28% sequence
identity), whereas the carboxyl terminus (amino
acids 435–523) contains a CARD motif instead of the
structurally related DD found in RIP. The intermediate
region (amino acids 295–434) shows no significant homol-
ogy to any presently known protein. By northern blot
analysis (see Supplementary material published with this
paper on the internet), CARDIAK was found to be
expressed in several human tissues and cell lines, with two
transcript sizes of approximately 1.9 kb and 2.5 kb.
Highest expression was found in placenta, pancreas and
peripheral blood leukocytes (PBLs). The transformed 
B-cell line Raji also expressed high levels of CARDIAK
mRNA, suggesting that the strong signal in PBLs may be
derived from B lymphocytes.
We next tested the predicted serine/threonine kinase
activity of CARDIAK in an in vitro kinase assay.
SDS–PAGE analysis revealed a 32P-labeled 65–68 kDa
band, indicating that CARDIAK is a protein kinase that
undergoes autophosphorylation. The kinase activity was
lost when Asp146, an invariant residue found in all protein
kinases and shown to be essential for the enzymatic activ-
ity of the c-Kit kinase [7,8], was mutated to Asn
(CARDIAK(D146N), Figure 1b). 
We next assessed effector functions that had been
described for RIP — the induction of apoptosis and the
activation of NF-κB and JNK [1,8,9]. Whereas overexpres-
sion of TRADD and RIP in 293T cells led to extensive
cell death, cells overexpressing CARDIAK did not display
characteristic features of apoptosis (data not shown).
Coexpression of CARDIAK with JNK in 293T cells
potently induced JNK activation compared with the activ-
ity resulting from coexpression with the vector control
(Figure 2a). It is unlikely that CARDIAK directly acti-
vated JNK by phosphorylation, as the kinase-defective
CARDIAK(D146N) activated JNK as potently as the
wild-type kinase. A CARDIAK construct containing the
kinase and intermediate domain (amino acids 7–425)
failed to activate JNK, whereas weak but reproducible
JNK activation was observed with a construct containing
the CARD motif alone (amino acids 431–540).
As RIP-deficient mice have an impaired NF-κB signaling
pathway [3], we investigated whether CARDIAK was able
to activate NF-κB using a luciferase reporter gene driven
by NF-κB-binding sites. Expression of CARDIAK in
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Figure 1
Structure and enzymatic activity of CARDIAK.
(a) Predicted amino acid sequence of human
CARDIAK, which contains a kinase domain
and a CARD motif linked by a connecting
region of approximately 140 amino acids. The
kinase domain of CARDIAK is aligned with the
kinase domain of human RIP (GenBank
accession U50062), and the CARD motif is
aligned with the CARD motifs of the equine
herpes virus-2 E10 protein, RAIDD, caspase-1,
caspase-2, caspase-9, c-IAP1 and APAF-1
[5]. Black boxes indicate greater than 50%
amino acid sequence identity and gray
shading indicates greater than 50% sequence
similarity through conservative amino acid
substitutions. The amino acid position
mutated to generate a kinase-inactive
CARDIAK (D146N), is marked by a star. 
(b) Kinase activity of CARDIAK. Lysates from
293T cells expressing vesicular stomatitis
virus (VSV)-tagged wild-type CARDIAK or
kinase-defective CARDIAK(D146N) and from
control transfectants were subjected to
immunoprecipitation and in vitro kinase assay
[13] followed by SDS–PAGE and western
blotting, and the membrane was subjected to
autoradiography (upper panel, CARDIAK-P) or
immunoblot analysis with anti-VSV antibody
(P5D4, Sigma; lower panel). Numbers on the
left refer to marker sizes in kDa.
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Activation of JNK and NF-κB by CARDIAK. (a) Activation of JNK by
CARDIAK. Cells (293T) were transfected by calcium-phosphate
precipitation with 3 µg JNK expression construct in combination with
the indicated wild-type (wt) or mutated (m, D146N) CARDIAK
constructs: full-length CARDIAK, its kinase and intermediate domain
(kinase+IM, amino acids 7–425) or the CARD region (amino
acids 431–540). Cells were lysed 30 h after transfection by three
freeze–thaw cycles in lysis buffer containing 1% NP-40, 20 mM Tris-
HCl pH 7.4, 150 mM NaCl and protease inhibitors (Complete,
Boehringer), and JNK activation was determined by western blotting
using an antibody specific for active, phosphorylated JNK (Promega).
The lower two panels show the expression levels of FLAG-tagged JNK
and of the VSV-tagged CARDIAK by anti-FLAG immunoblotting (M2,
Kodak International Biotechnologies) and anti-VSV immunoblotting,
respectively. Protein sizes in kDa are shown to the left of the blot.
(b–d) Activation of NF-κB by CARDIAK. Cells (293T) were
cotransfected with 1 µg NF-κB luciferase reporter plasmid 
(pNF-κBluc), 0.5 µg pCMV β-gal (as an internal transfection efficiency
control), the indicated CARDIAK constructs and, where indicated, with
a dominant negative TRAF2 construct (TRAF2-DN), and empty vector
to give 6 µg total DNA. Luciferase activities were determined as
previously described [14]. Values shown are averages for
representative experiments in which each transfection was carried out
in duplicate.
293T cells indeed resulted in a dose-dependent activation
of the reporter gene, reaching an almost 35-fold increase
in luciferase activity compared with the control vector
(Figure 2b). As was found with JNK, the activation of 
NF-κB was independent of CARDIAK kinase activity.
CARDIAK constructs encompassing the intermediate
domain with the wild-type or the inactive kinase domain
failed to activate NF-κB, whereas the CARD-containing
carboxyl terminus weakly induced NF-κB activation
(Figure 2c). 
The TNFR family members can activate NF-κB by recruit-
ing specific members of the TRAF family, two of which,
TRAF1 and TRAF2, were initially identified as compo-
nents of the TNFR-2 signaling complex [9]. Expression of a
dominant-negative form of TRAF2 in 293T cells blocked
NF-κB activation induced by CARDIAK (Figure 2c), but
not JNK activation induced by CARDIAK (data not shown),
indicating that CARDIAK may act upstream of TRAF2 in
ΝF-κΒ activation induced by one of the TNFR family
members. As both TRAF1 and TRAF2 have been shown to
bind to RIP [10], we investigated whether TRAF1 and
TRAF2 physically interacted with CARDIAK. Tagged ver-
sions of CARDIAK and either TRAF1 or TRAF2 were
transiently expressed in 293T cells. Subsequent immuno-
precipitation revealed that both TRAF1 and TRAF2 pro-
teins associated with CARDIAK (Figure 3a,b). 
We also searched for possible CARD-containing binding
partners of CARDIAK. Several different FLAG-tagged
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Interaction of CARDIAK with TRAFs, c-IAPs and caspase-1. 
(a,b) Interaction of CARDIAK with TRAF1 and TRAF2. Cells (293T)
were cotransfected with the indicated expression vectors, and anti-
FLAG immunoprecipitates (IP) were prepared and analysed [15] for
coprecipitating molecules by immunoblotting using anti-VSV and anti-
AU-1(a 6 amino acid epitope of the bovine papilloma virus capsid
protein) antibodies (BAbCO), respectively. For (a–e), the expression
levels of the transfected proteins in the cell extracts are shown in the
lower panels. (c) Interaction of CARDIAK with c-IAPs. Expression
vectors for hemagglutinin (HA)-tagged CARDIAK and for FLAG-
tagged c-IAP1 and c-IAP2 were cotransfected into 293T cells as
indicated, and anti-FLAG immunoprecipitates were analysed for the
presence of CARDIAK by immunoblotting using anti-HA antibody
(HA.11, BAbCO). The coimmunoprecipitation protocol used for the
analysis of c-IAP binding to CARDIAK has been described elsewhere
[4]. (d,e) Interaction of CARDIAK with caspase-1. Cells (293T) were
transfected, as indicated, with expression vectors for VSV-tagged
CARDIAK and for FLAG-tagged caspase-1, caspase-2 (Ich1s),
caspase-4, caspase-9, RAIDD and E10 of equine herpes virus-2.
FLAG-tagged full-length (FL) caspase-1 or its CARD region (amino
acids 2–92) were used in (e). The caspase inhibitor zVAD-fmk (50 µM)
was added after transfection for the experiment shown in (d) to prevent
the cytotoxic effects of caspase overexpression. Anti-FLAG
immunoprecipitates were prepared and analysed [15] for the presence
of CARDIAK by immunoblotting using anti-VSV antibody. A shorter
exposure is shown for the lower part of of the anti-FLAG western blot
in (e). (f) Activation of pro-caspase-1 by CARDIAK. Cells (293T) were
cotransfected with expression vectors for the full-length, carboxy-
terminally FLAG-tagged caspase-1 (5 µg) and either 3 µg or 0.3 µg of
wt or mutated (D146N) CARDIAK, as indicated. Cell extracts were
analysed 24 h after transfection for the presence of FLAG–caspase-1
(upper panel) or of the p20 active subunit of caspase-1 (lower panel)
by immunoblotting using anti-FLAG or anti-p20 antibodies (a gift of J.
Yuan), respectively. In (a–f), protein sizes in kDa are shown to the left
of the blots.
CARD-containing proteins [5] were expressed in 293T
cells and assayed for their ability to interact with coex-
pressed CARDIAK. We found that cellular inhibitor of
apoptosis protein 1 (c-IAP1) and to a lesser extent, c-IAP2
which together with TRAF1 and TRAF2 both form part
of the TNFR-2 signaling complex [11], coprecipitated a
small amount of CARDIAK (Figure 3c). As truncated 
c-IAPs containing only the CARD region did not interact
with CARDIAK (data not shown), it is likely that the
weak CARDIAK–c-IAP interaction is indirect, potentially
mediated by TRAF1 and/or TRAF2. In contrast, a strong
interaction between CARDIAK and caspase-1 was
detected, whereas other CARD-containing proteins
(caspase-2, caspase-4, caspase-9, RAIDD and the viral
protein E10) were unable to coprecipitate CARDIAK
(Figure 3d). The association between CARDIAK and
caspase-1 was mediated by the CARD motifs in the two
molecules, as a truncated caspase-1 molecule containing
only the CARD motif (amino acids 2–92) could interact
with CARDIAK (Figure 3e), and a CARDIAK construct
lacking the CARD did not coprecipitate with caspase-1
(data not shown). Moreover, expression of CARDIAK
together with caspase-1 led to the processing of caspase-1,
resulting in the formation of the p20 active subunit of
caspase-1 (Figure 3f). The activation of caspase-1 by
CARDIAK correlated with the amount of cotransfected
CARDIAK. It did not require the kinase activity of
CARDIAK, and it could be inhibited by coexpression of
the CARD of CARDIAK (Figure 3f and data not shown).
In summary, we have identified a RIP-like serine/threo-
nine kinase, CARDIAK, which may be implicated in the
regulation of signaling pathways initiated by TNFR
family members. CARDIAK overexpression leads to JNK
and NF-κB activation, and the observed ΝF-κΒ activation
correlates with a physical and functional interaction of
CARDIAK with TRAF2. CARDIAK appears to bind
directly to the CARD-containing pro-domain of caspase-1,
and coexpression of CARDIAK with pro-caspase-1 corre-
lates with the formation of active caspase-1. Little is
known about the molecular mechanism that leads to
caspase-1 activation, but it is likely to involve the recruit-
ment of pro-caspase-1, through its CARD motif, by one of
the TNFR family members. Indeed, stimulation of CD40
has been shown to activate caspase-1 in vascular smooth
muscle and endothelial cells with the subsequent release
of the active proinflammatory IL-1β [12]. Although the
physiological function of CARDIAK is not known as yet,
ongoing studies aim to assess the precise role of
CARDIAK in the NF-kB and JNK pathways, as well as
the potential effect of CARDIAK on caspase-1 activation
and inflammation.
Supplementary material
A figure showing CARDIAK mRNA expression in various human tissues
and cell lines, and details of the expression vectors used in this study
are published with this paper on the internet. 
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Material and methods
Expression vectors
The following CARD-containing proteins or protein fragments were
amplified using Pwo polymerase (Boehringer) by standard PCR
methods with the indicated specific primers with suitable restriction
sites on 5′ and 3′ ends, on cDNA templates from the indicated
sources: full-length human CARDIAK (amino acids 2–540) and the
carboxy-terminal CARD of CARDIAK (amino acids 431–540) were
amplified using oligos JT676 (5′ AACGGGGAGGCCATCT-
GCAGCG 3′) and JT677 (5′ CTCGAGCAGTCACTTACATGCTTT-
TATT 3′) and oligos JT848 (5′ CTGCAGCCTGGTATAGCCCAG
3′) and JT677, respectively, on EST clone 799136; E10 of EHV-2
(amino acids 2–311) was amplified using oligos JT672 (5′
CTGCAGCCTGGTATAGCCCAG 3′) and JT673 (5′ CTCGAGTT-
TAGCAGCAGAAAAACCTCC 3′) on viral EHV-2 DNA (a gift of A.J.
Davison). The CARD region of human caspase-1 (amino acids 2–92)
was amplified using oligos JT846 (5′ CTGCAGAGCCGACAAGGTC-
CTGAAG 3′)and JT847 (5′ GCGGCCGCTAATCTGCTGAGAGTC-
CCAG 3′), full-length human caspase-2 (Ich-1S) using oligos JT633
(5′ CGGAATTCATGCATCCTCATCATCAG 3′) and JT634 (5′
GCTCTAGATCATAGAGCAAGAGAGGC 3′) and caspase-9 using
oligos JT842 (5′ GACGAAGCGGATCGGCGGCTC 3′) and JT849
(5′ TTATGATGTTTTAAAGAAAAGTTT 3′: the cDNAs for human
caspase-1, 2 and 9 were a gift of C.J. Froelich. Full-length human
caspase-4 was amplified using oligos JT840 (5′ CTGCAGAGCA-
GAAGGCAACCACAGA 3′) and JT1054 (5′ GTCGA-
CATTGCCAGGAAAGAGGTAG 3′: the cDNA was a gift of J. Yuan,
c-IAP1 and c-IAP2 were amplified using oligos JT612 (5′
CGGAATTCATGCACAAAACTGCCTC 3′) and JT613 (5′ TCTCC-
CGGGTTAAGAGAGAAATGTACG 3′), and using oligos JT614 (5′
CGGAATTCATGAACATAGTAGAAAAC 3′) and JT615 (5′ GCTC-
TAGATCATGAAAGAAATGTACG 3′), respectively: the cDNA was
kindly provided by D. Goeddel. 
Mutation of the kinase domain of CARDIAK (Asp146 to Asn, D146N)
was achieved by site-directed mutagenesis with two sequential rounds
of PCR, using oligos JT676 and JT677 (see above) in combination with
JT924 (5′ CATCATAATTTAAAGACTCAGAATATC 3′) and JT925 
(5′ GAGTCTTTAAATTATGATGAAGTAA 3′) which altered Asp146
to Asn and introduced a silent mutation creating a DraI site for screen-
ing of the cloned mutated PCR product. 
PCR products were cloned into pCRblunt (Invitrogen), followed by
subcloning into derivatives of pCR3 (Invitrogen), in frame with a
carboxy-terminal FLAG tag (caspase-4) or with an amino-terminal
FLAG tag, VSV tag or HA tag (all others). 
Human RAIDD was amplified with Taq polymerase (GIBCO) using
oligos JT595 (5′ AATGGAGGCGCAGAGACAAAC 3′) and JT596
(5′ AGCGGTTGCTGGAGGCACC 3′) on EST clone 140648; the
PCR product was cloned into pCR2.1 (Invitrogen) and subcloned,
using the EcoRI sites in the vector, into a pCR3-derived expression
vector, in frame with an amino-terminal FLAG tag. 
All above described cloned PCR products were checked by sequenc-
ing to ensure that no errors had been introduced by PCR.
Constructs containing the kinase domain (wild-type or mutated) and
the intermediate domain of CARDIAK were obtained by subcloning of a
PstI fragment (nucleotides 22–1275) of the wild-type or the mutated
CARDIAK cDNA into a pCR3-derived expression vector, in-frame with
an amino-terminal VSV tag. 
The following expression plasmids were obtained from the indicated
sources: NF-κBluc (V. Jongeneel); FLAG–JNK (C. Widmann);
GFP–hTRAF2 (amino acids 87–501) and FLAG-tagged mTRAF1 (H.
Wajant); AU1-tagged hTRAF2 (H. Engelmann); and carboxy-terminally
FLAG-tagged caspase-1 (J. Yuan).
Supplementary material
Figure S1
Northern blot showing the tissue distribution
of CARDIAK transcripts. Northern blots of
various human tissues and tumor cell lines
(Clontech) were hybridized with a 32P-labeled
cDNA probe that hybridizes to the kinase and
the intermediate domain of human CARDIAK
(a PstI fragment corresponding to nucleotides
22–1275) and the blots were subsequently
hybridized with β-actin.
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